Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma

Abstract Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) are genetically complex soft tissue sarcomas with distinct morphological features. Treatment typically involves surgery, often combined with neoadjuvant chemo- or radiotherapy. To better understand the immunobiology of th...

Full description

Saved in:
Bibliographic Details
Main Authors: Siddh van Oost, Debora M. Meijer, Zeynep B. Erdem, Marieke E. IJsselsteijn, Jessica Roelands, Suk Wai Lam, Melissa S. Boejharat, Brendy E. W. M. van den Akker, Ruud van der Breggen, Inge H. Briare-de Bruijn, Lukas J. A. C. Hawinkels, Anouk A. Kruiswijk, Manon van der Ploeg, Pauline M. Wijers-Koster, Rick L. Haas, Michiel A. J. van den Sande, Noel F. C. C. de Miranda, Judith V. M. G. Bovee
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Online Access:https://doi.org/10.1007/s00262-025-04123-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234932657815552
author Siddh van Oost
Debora M. Meijer
Zeynep B. Erdem
Marieke E. IJsselsteijn
Jessica Roelands
Suk Wai Lam
Melissa S. Boejharat
Brendy E. W. M. van den Akker
Ruud van der Breggen
Inge H. Briare-de Bruijn
Lukas J. A. C. Hawinkels
Anouk A. Kruiswijk
Manon van der Ploeg
Pauline M. Wijers-Koster
Rick L. Haas
Michiel A. J. van den Sande
Noel F. C. C. de Miranda
Judith V. M. G. Bovee
author_facet Siddh van Oost
Debora M. Meijer
Zeynep B. Erdem
Marieke E. IJsselsteijn
Jessica Roelands
Suk Wai Lam
Melissa S. Boejharat
Brendy E. W. M. van den Akker
Ruud van der Breggen
Inge H. Briare-de Bruijn
Lukas J. A. C. Hawinkels
Anouk A. Kruiswijk
Manon van der Ploeg
Pauline M. Wijers-Koster
Rick L. Haas
Michiel A. J. van den Sande
Noel F. C. C. de Miranda
Judith V. M. G. Bovee
author_sort Siddh van Oost
collection DOAJ
description Abstract Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) are genetically complex soft tissue sarcomas with distinct morphological features. Treatment typically involves surgery, often combined with neoadjuvant chemo- or radiotherapy. To better understand the immunobiology of these sarcomas and its associations with treatment response and prognosis, we performed transcriptomic and immunophenotypic profiling. RNA sequencing was performed on 13 UPS and 10 MFS, and immunological profiles were compared with soft tissue sarcoma data from The Cancer Genome Atlas (n = 206 including 44 UPS and 17 MFS). Immune contextures were further evaluated in 14 UPS and 15 MFS using imaging mass cytometry. Characterization of T cell and macrophage infiltration in tumors was further assessed in 23 UPS and 22 MFS through multispectral immunofluorescence and immunohistochemical analysis. UPS and MFS demonstrated immunogenic features compared to other soft tissue sarcomas, with subsets of UPS and MFS demonstrating high T cell infiltration, while UPS demonstrated a higher infiltration by myeloid cells as compared to MFS. Prognostically, T cells and CD68+CD163+ macrophages were associated with metastasis-free survival in UPS but not in MFS. Notably, in UPS, neoadjuvant radiotherapy appeared to induce cytotoxic T cell infiltration and depletion of myeloid cells, whereas these effects were not observed in MFS. These findings highlight important differences in the immunobiology of UPS and MFS with therapeutic and prognostic implications. These differences should be taken into account given the growing availability of immunotherapeutic options for treating patients with soft tissue sarcomas.
format Article
id doaj-art-b529a166eb844cbebaf3318a52c5e51d
institution Kabale University
issn 1432-0851
language English
publishDate 2025-07-01
publisher Springer
record_format Article
series Cancer Immunology, Immunotherapy
spelling doaj-art-b529a166eb844cbebaf3318a52c5e51d2025-08-20T04:02:57ZengSpringerCancer Immunology, Immunotherapy1432-08512025-07-0174811410.1007/s00262-025-04123-yDivergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcomaSiddh van Oost0Debora M. Meijer1Zeynep B. Erdem2Marieke E. IJsselsteijn3Jessica Roelands4Suk Wai Lam5Melissa S. Boejharat6Brendy E. W. M. van den Akker7Ruud van der Breggen8Inge H. Briare-de Bruijn9Lukas J. A. C. Hawinkels10Anouk A. Kruiswijk11Manon van der Ploeg12Pauline M. Wijers-Koster13Rick L. Haas14Michiel A. J. van den Sande15Noel F. C. C. de Miranda16Judith V. M. G. Bovee17Department of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Gastroenterology and Hepatology, Leiden University Medical CenterDepartment of Orthopedic Surgery, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Radiotherapy, The Netherlands Cancer InstituteDepartment of Orthopedic Surgery, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterDepartment of Pathology, Leiden University Medical CenterAbstract Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) are genetically complex soft tissue sarcomas with distinct morphological features. Treatment typically involves surgery, often combined with neoadjuvant chemo- or radiotherapy. To better understand the immunobiology of these sarcomas and its associations with treatment response and prognosis, we performed transcriptomic and immunophenotypic profiling. RNA sequencing was performed on 13 UPS and 10 MFS, and immunological profiles were compared with soft tissue sarcoma data from The Cancer Genome Atlas (n = 206 including 44 UPS and 17 MFS). Immune contextures were further evaluated in 14 UPS and 15 MFS using imaging mass cytometry. Characterization of T cell and macrophage infiltration in tumors was further assessed in 23 UPS and 22 MFS through multispectral immunofluorescence and immunohistochemical analysis. UPS and MFS demonstrated immunogenic features compared to other soft tissue sarcomas, with subsets of UPS and MFS demonstrating high T cell infiltration, while UPS demonstrated a higher infiltration by myeloid cells as compared to MFS. Prognostically, T cells and CD68+CD163+ macrophages were associated with metastasis-free survival in UPS but not in MFS. Notably, in UPS, neoadjuvant radiotherapy appeared to induce cytotoxic T cell infiltration and depletion of myeloid cells, whereas these effects were not observed in MFS. These findings highlight important differences in the immunobiology of UPS and MFS with therapeutic and prognostic implications. These differences should be taken into account given the growing availability of immunotherapeutic options for treating patients with soft tissue sarcomas.https://doi.org/10.1007/s00262-025-04123-yUndifferentiated pleomorphic sarcomasMyxofibrosarcomasImmune microenvironmentMetastasis-free survivalRadiotherapy
spellingShingle Siddh van Oost
Debora M. Meijer
Zeynep B. Erdem
Marieke E. IJsselsteijn
Jessica Roelands
Suk Wai Lam
Melissa S. Boejharat
Brendy E. W. M. van den Akker
Ruud van der Breggen
Inge H. Briare-de Bruijn
Lukas J. A. C. Hawinkels
Anouk A. Kruiswijk
Manon van der Ploeg
Pauline M. Wijers-Koster
Rick L. Haas
Michiel A. J. van den Sande
Noel F. C. C. de Miranda
Judith V. M. G. Bovee
Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
Cancer Immunology, Immunotherapy
Undifferentiated pleomorphic sarcomas
Myxofibrosarcomas
Immune microenvironment
Metastasis-free survival
Radiotherapy
title Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
title_full Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
title_fullStr Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
title_full_unstemmed Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
title_short Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
title_sort divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
topic Undifferentiated pleomorphic sarcomas
Myxofibrosarcomas
Immune microenvironment
Metastasis-free survival
Radiotherapy
url https://doi.org/10.1007/s00262-025-04123-y
work_keys_str_mv AT siddhvanoost divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT deborammeijer divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT zeynepberdem divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT mariekeeijsselsteijn divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT jessicaroelands divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT sukwailam divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT melissasboejharat divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT brendyewmvandenakker divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT ruudvanderbreggen divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT ingehbriaredebruijn divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT lukasjachawinkels divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT anoukakruiswijk divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT manonvanderploeg divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT paulinemwijerskoster divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT ricklhaas divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT michielajvandensande divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT noelfccdemiranda divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma
AT judithvmgbovee divergenttherapeuticandprognosticimpactsofimmunogenicfeaturesinundifferentiatedpleomorphicsarcomaandmyxofibrosarcoma